BMB-101 is under clinical development by Bright Minds Biosciences and currently in Phase II for Absence Seizure. According to GlobalData, Phase II drugs for Absence Seizure does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BMB-101 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BMB-101 overview
BMA-101 is under development for the treatment of absence seizure disorder, developmental and epileptic encephalopathy (DEE) such as Dravet syndrome or Lennox-Gastaut syndrome, opioid use disorder, binge eating disorder and Alzheimer's disease. It acts by targeting 5-hydroxytryptamine receptor 2C (5 HT2C). It is administered through oral route in the form of liquid.
Bright Minds Biosciences overview
Bright Minds Biosciences (Bright Minds) is a biotechnology company that discovers and develops treatments for neuropsychiatry disorders, epilepsy, and pain. The company’s pipeline products include BMB-101 selective and biased 2C agonist, a low 5-HT 2A/2B that targets Dravet syndrome; and BMB-202 a selective 5-HT2a that treats depression, anxiety and post-traumatic stress disorder. It utilizes intelligent drug design and advanced molecular modeling technology to develop its products. The company works in collaboration with the National Institutes of Health (NIH), the University of Texas Medical Branch, the Medical College of Wisconsin and Katholieke University Leuven. Bright Minds is headquartered in New York, the US.
For a complete picture of BMB-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
